Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Enhancing Patient Care Through Standardized Germline Reporting in Oncology Testing

NSGC 2025

National Society of Genetic Counselors

Seattle, WA, Nov 6-10, 2025

Oral presentation: Enhancing Patient Care Through Standardized Germline Reporting in Oncology Testing

Authors: Johnson R, Terhaar C, Nordquist E, Loo E, Kruzel M

Medical Specialty: Genetics, Oncology

Related content

Test FAQ
Comprehensive Hereditary Cancer Panel
On-Demand Webinar
Early Detection Better Protection - Colorectal Cancer Screening in the Workplace: A Panel Discussion
Publication
Phenotypes of Carriers of Two Mutated Alleles in Major Cancer Susceptibility Genes
Publication
Probing the Relevance of BRCA1 and BRCA2 Germline Pathogenic Variants Beyond Breast and Ovarian Cancer
On-Demand Webinar
Unwinding with DDX41 A case presentation regarding DDX41 and its germline predisposition to myeloid neoplasms

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.